Browse result page of B3Pdb

The total number entries retrieved from this search are 18, scroll left/right for detailed information.

B3pdbID	PEPTIDE NAME	PEPTIDE SEQUENCE (1-letter)	PEPTIDE SEQUENCE (3-letter)	N-TERMINAL MODIFICATION	C-TERMINAL MODIFICATION	CHEMICAL MODIFICATION	PEPTIDE LENGTH	PEPTIDE CONFORMATION	PEPTIDE NATURE	SOURCE/ORIGIN OF PEPTIDE	SMILES	CELL LINE	In vitro CONCENTRATION	In vitro METHOD	In vitro RESULT	ANIMAL MODEL	In vivo CONCENTRATION	In vivo MODE OF DELIVERY	In vivo METHOD	In vivo RESULT	ACTION	TRANSPORT TYPE	SUBCELLULAR LOCALISATION	COMBINATION	PHYSICAL CONDITION	RESPONSE	RESULT	LABEL	PMID
B3pdbIDb3pdb_0004	PEPTIDE NAMENA	PEPTIDE SEQUENCE (1-letter)SLKP	PEPTIDE SEQUENCE (3-letter)SerLeuLysPro	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATION5(6)-carboxyfluorescein attched to peptide	PEPTIDE LENGTH4	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEDodeca-neuropeptide (SLKPAANLPLRF) of frog brain.	SMILESN[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N1[C@@]([H])(CCC1)C(=O)O	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELRat primary cortical neurons	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODFourier Transform Infrared Spectroscopy	In vivo RESULTInhibition of Aβ fibrillation	ACTIONIt inhibits Aβ fibrillization, moderately binds with tubulin and promotes tubulin polymerization as	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer’s disease	RESPONSENA	RESULTNA	LABELNA	PMID 30408415
B3pdbIDb3pdb_0005	PEPTIDE NAMER-Rfa	PEPTIDE SEQUENCE (1-letter)SLKPAANLPLRF	PEPTIDE SEQUENCE (3-letter)SerLeuLysProAlaAlaAsnLeuProLeuArgPhe	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATION5(6)-carboxyfluorescein attched to peptide	PEPTIDE LENGTH12	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEDodeca-neuropeptide (SLKPAANLPLRF) of frog brain.	SMILESN[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELRat primary cortical neurons	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODFourier Transform Infrared Spectroscopy	In vivo RESULTInhibition of Aβ fibrillation	ACTIONIt inhibits Aβ fibrillization, moderately binds with tubulin and promotes tubulin polymerization as	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer’s disease	RESPONSENA	RESULTNA	LABELNA	PMID 30408415
B3pdbIDb3pdb_0038	PEPTIDE NAMEApoB11	PEPTIDE SEQUENCE (1-letter)RLTRKRGLKLA	PEPTIDE SEQUENCE (3-letter)ArgLeuThrArgLysArgGlyLeuLysLeuAla	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION 5 Gly (G) and 9 Arg (R) amino acids to the C-termi	CHEMICAL MODIFICATIONCoupled with a 9-amiNA acid arginine linker	PEPTIDE LENGTH11	PEPTIDE CONFORMATIONNA	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEApoB38 peptide	SMILESN[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)O	CELL LINEMouse cholinergic cell line Neuro2A (N2A)	In vitro CONCENTRATION100000 cells/well	In vitro METHODLaser scanning confocal microscopy	In vitro RESULTIt crosses the BBB with conguagted siRNA for alpha-syn.	ANIMAL MODELTransgenic Mice	In vivo CONCENTRATION50 microgram	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODLaser scanning confocal microscopy	In vivo RESULTIt can transport siα-syn across the BBB as a therapeutic option for synucleinopathies.	ACTIONIt showed reduced accumulation of α-syn associated with amelioration of the neurodegenerative and i	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNeurons and glial cellsexhibiting α-syn accumulation	COMBINATIONCombined with siRNA for alpha-syn	PHYSICAL CONDITIONLewy body disease	RESPONSENA	RESULTNA	LABELNA	PMID 30849508
B3pdbIDb3pdb_0039	PEPTIDE NAMEC2-9r	PEPTIDE SEQUENCE (1-letter)CDIFTNSRGKRA	PEPTIDE SEQUENCE (3-letter)CysAspIlePheThrAsnSerArgGlyLysArgAla	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION 4 Gly (G) and nine d-Arg (9r) residues to the Cter	CHEMICAL MODIFICATIONCoupled with a 9-amiNA acid arginine linker	PEPTIDE LENGTH12	PEPTIDE CONFORMATIONNA	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDErhabdovirus glycoprotein	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)O	CELL LINEMouse cholinergic cell line Neuro2A (N2A)	In vitro CONCENTRATION100000 cells/well	In vitro METHODLaser scanning confocal microscopy	In vitro RESULTIt crosses the BBB with conguagted siRNA for alpha-syn.	ANIMAL MODELTransgenic Mice	In vivo CONCENTRATION50 microgram	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODLaser scanning confocal microscopy	In vivo RESULTIt can transport siα-syn across the BBB as a therapeutic option for synucleinopathies.	ACTIONIt showed reduced accumulation of α-syn associated with amelioration of the neurodegenerative and i	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNeurons and glial cellsexhibiting α-syn accumulation	COMBINATIONCombined with siRNA for alpha-syn	PHYSICAL CONDITIONLewy body disease	RESPONSENA	RESULTNA	LABELNA	PMID 30849508
B3pdbIDb3pdb_0065	PEPTIDE NAMEAng-2	PEPTIDE SEQUENCE (1-letter)CTFFYGGSRGKRNNFKTEE	PEPTIDE SEQUENCE (3-letter)CysThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGlu	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH19	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEChemically synthesized	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)O	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELC57BL6 mice	In vivo CONCENTRATION1 mg/mL	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODFluorescent microscopy	In vivo RESULTLocalization of the nanoparticle within the brain cells, highlighting in particular the neuron accum	ACTIONBrain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus	TRANSPORT TYPETranscytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONConjugated to poly(lactic-co-glycolic acid) (PLGA)	PHYSICAL CONDITIONNA	RESPONSENA	RESULTNA	LABELNA	PMID 31963430
B3pdbIDb3pdb_0140	PEPTIDE NAMEMet-Enkephalins	PEPTIDE SEQUENCE (1-letter)YGGFM	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Met-OH	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION20 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 2 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0141	PEPTIDE NAMELeu-Enkephalins	PEPTIDE SEQUENCE (1-letter)YGGFL	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Leu-OH	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION20 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 2 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0142	PEPTIDE NAMEFmoc-Met-Enkephalin	PEPTIDE SEQUENCE (1-letter)YGGFM	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Met-OH	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONAddition of Fmoc group towards N terminal	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION20 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 2 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0143	PEPTIDE NAMEFmoc-Leu-Enkephalins	PEPTIDE SEQUENCE (1-letter)YGGFL	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Leu-OH	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONAddition of Fmoc group towards N terminal	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION20 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 4 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0144	PEPTIDE NAMEFmoc-Leu-Enkephalins	PEPTIDE SEQUENCE (1-letter)YGGFL	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Leu-OH	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONAddition of Fmoc group towards N terminal	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION10 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 4 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0145	PEPTIDE NAMEHOOC-(CH2)10-Leu-Enk	PEPTIDE SEQUENCE (1-letter)YGGFL	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Leu-OH	N-TERMINAL MODIFICATIONAddition of HOOC-(CH2)10 group to Fmoc	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONAddition of HOOC-(CH2)10 group to Fmoc	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION10 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 3 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0146	PEPTIDE NAMEFmoc-Leu-Enkephalins	PEPTIDE SEQUENCE (1-letter)YGGFL	PEPTIDE SEQUENCE (3-letter)Tyr-Gly-Gly-Phe-Leu-OH	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONEnd to end joining of two Fmoc-Leu-Enkephalin	PEPTIDE LENGTH5	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELICR male mice	In vivo CONCENTRATION10 micromole/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODHot water tail flick test	In vivo RESULTAnalgesic effect seen within 3.5 seconds	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22778833
B3pdbIDb3pdb_0147	PEPTIDE NAMEGoldnanoparticle con	PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP	PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONConjugated with CLPFFD goldnaNAparticle	PEPTIDE LENGTH12	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDEChemically synthesized	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELAdult Sprague-Dawley rats	In vivo CONCENTRATION1.86 mg/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODInstrumental neutron activation analysis and Nissl staining	In vivo RESULTConjugate was found to cross blodd brain barrier; does not effect mice survival; no toxicity as meas	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22795856
B3pdbIDb3pdb_0148	PEPTIDE NAMEPACAP-TAT peptide	PEPTIDE SEQUENCE (1-letter)PACAP-YGRKKRRQRRR	PEPTIDE SEQUENCE (3-letter)PACAP-TyrGlyArgLysLysArgArgGlnArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION Conjugated with TAT	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTHNA	PEPTIDE CONFORMATIONCyclic	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENatural from pituitary gland	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELMale NIH mouse	In vivo CONCENTRATION100 nmol/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODFluoroscent screening by FITC labbled peptide maass in brain tissue	In vivo RESULTcrosses blood brain barrier with 6.55+/-0.55% efficacy	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22939769
B3pdbIDb3pdb_0149	PEPTIDE NAMEPACAP-TAT peptide	PEPTIDE SEQUENCE (1-letter)PACAP-YGRKKRRQRRR	PEPTIDE SEQUENCE (3-letter)PACAP-TyrGlyArgLysLysArgArgGlnArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTHNA	PEPTIDE CONFORMATIONCyclic	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENatural from pituitary gland	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELMale NIH mouse	In vivo CONCENTRATION100 nmol/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODFluoroscent screening by FITC labbled peptide maass in brain tissue	In vivo RESULTcrosses blood brain barrier with 2.77+/-0.88% efficacy	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONAlzheimer	RESPONSENA	RESULTNA	LABELNA	PMID 22939769
B3pdbIDb3pdb_0150	PEPTIDE NAMEMMP-2200	PEPTIDE SEQUENCE (1-letter)Y-D-TGFLS(β-O-Glc)-CONH2	PEPTIDE SEQUENCE (3-letter)Tyr-D-Thr-Gly-Phe-Leu-Ser(β-O-Glc)-CONH2	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONGlycosylated serine residue	PEPTIDE LENGTH6	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEChemically synthesized	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELAdult Sprague-Dawley rats	In vivo CONCENTRATION10mg/Kg	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODMicrodialysis analysis and LCMS analysis	In vivo RESULTSignificant amount of peptide crosses blood brain barrier after 12 minute and remain stable up to 80	ACTIONShows potent analgesic behaviour	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONParkinson	RESPONSEStability/half life	RESULT80 minute	LABELNA	PMID 23127847
B3pdbIDb3pdb_1208	PEPTIDE NAMEAdiponetic peptide	PEPTIDE SEQUENCE (1-letter)LQVYGDGDHNGLYADNVN	PEPTIDE SEQUENCE (3-letter)NA	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH18	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELC57BL/6J mice	In vivo CONCENTRATION15 mg/kg of APNp	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODFourier Transform Infrared Spectroscopy	In vivo RESULTAPNp suppressed mitochondrial and ATF4-CHOP apoptosis pathways in a Smad3 dependent manner.	ACTIONNA	TRANSPORT TYPEPermeability	SUBCELLULAR LOCALISATIONNA	COMBINATIONAlone	PHYSICAL CONDITIONICH injury in diabetic mice	RESPONSENA	RESULTAPNp promoted neural sur- vival following ICH injury in the diabetic setting, by suppressing mitocho	LABELNA	PMID 31922310
B3pdbIDb3pdb_1218	PEPTIDE NAMEdNP2	PEPTIDE SEQUENCE (1-letter)KIKKVKKKGRKGSKIKKVKKKGRK	PEPTIDE SEQUENCE (3-letter)NA	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH24	PEPTIDE CONFORMATIONNA	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDEChemically synthesized	SMILESNA	CELL LINEJurkat cells	In vitro CONCENTRATION2 μM	In vitro METHODConfocal microscopy	In vitro RESULTdNP2 enables the delivery of LRR domain of NLRX1 into T cells	ANIMAL MODELC57BL/6J Mice	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntraperitoneal	In vivo METHODConfocal microscopy	In vivo RESULTdNP2 enables the delivery of LRR domain of NLRX1 into T cells	ACTIONIt directly inhibits the functions of effector T cells and ameliorates disease severity of EAE with	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONCombined with LRR	PHYSICAL CONDITIONEncephalomyelitis	RESPONSENA	RESULTNA	LABELNA	PMID 32194859